Trading / Browse Companies / Tempest Therapeutics Stock

Tempest Therapeutics Stock

tempesttx.comBioTechFounded: 1900Funding to Date: $75.2MM

Tempest Therapeutics is a clinical-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.

Buy or sell Tempest Therapeutics stock
Register for Details

For more details on financing and valuation for Tempest Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Tempest Therapeutics.

Register Today
Register for Details

For more details on financing and valuation for Tempest Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Thomas Dubensky Ph.D
Chief Executive Officer, President & Board Member
Chan Whiting Ph.D
Senior Vice President of Research & Development
Ginna Laport MD
Chief Medical Officer
Peppi Prasit Ph.D
Acting Chief Scientific Officer & Director

Board Members

Bradley Bolzon Ph.D
Versant Venture Management
Peppi Prasit Ph.D
Robert Weisskoff Ph.D
F-Prime Capital Partners
Stella Xu Ph.D
Quan Capital
Thomas Dubensky Ph.D
Tempest Therapeutics
Thomas Woiwode Ph.D
Versant Venture Management

Other companies like Tempest Therapeutics in the BioTech sector

ANDE
Sector
BioTech
 
 
Mammoth Biosciences
Sector
BioTech
Last Round Est. Valuation
$1.08B
Arsenal Biosciences
Sector
BioTech
Last Round Est. Valuation
$185MM
Grail
Sector
BioTech
Last Round Est. Valuation
$4.26B
Life Biosciences
Sector
BioTech
Last Round Est. Valuation
$500MM
Synthego
Sector
BioTech
Last Round Est. Valuation
$1.3B
Caris Life Sciences
Sector
BioTech
 
 
Human Longevity
Sector
BioTech
Last Round Est. Valuation
$50.4MM
Ginkgo Bioworks
Sector
BioTech
Last Round Est. Valuation
$4.89B

News

Market Screener 11/08/2019
Tempest Therapeutics' Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting

Trending Companies

Frequently Asked Questions